Group items tagged

The Developmental Disabilities Assistance and Bill of Act (DD Act), requires that the programs authorized under the law are culturally competent to ensure that individuals with developmental disabilities, regardless of background, are full participants in all aspects of community life. According to the DD Act, Sec. 101. [42 USC 15001] c Policy. "It is the policy of the United States that all programs receiving assistance under this title shall be carried out in a manner consistent with the principles that Services, supports, and other assistance should be provided that demonstrate respect for personal preferences, and cultural differences; Specific efforts must be made to ensure that individuals with developmental disabilities from racial and ethnic minority backgrounds and their families enjoy increased and meaningful opportunities to access and use community services, individualized supports available to other individuals with developmental disabilities and their families; Recruitment efforts in disciplines related to developmental disabilities in pre-service training, community training, practice, administration, and Policymaking must focus on bringing larger numbers of racial and ethnic minorities into the disciplines in order to provide appropriate skills, knowledge, role models, and sufficient personnel to address the growing needs of an increasingly diverse population." The DD Act has long identified the importance of cultural competence and improving expectations and outcomes for people with developmental disabilities, including those from culturally and linguistically diverse backgrounds.

Established in 2002 as the Special Hope Foundation, the WITH (Working for Inclusive and Transformative Healthcare) Foundation provides financial support to organizations that promote delivery of comprehensive health care for adults with developmental disabilities. To that end, the foundation is accepting applications for its 2019 grants program. Through the program, grants of up to $50,000 will be awarded to programs that improve the delivery of health care to adults with developmental disabilities and that also include at least one of the following: improve health practitioner competency through education and/or training programs; address the current inadequate reimbursement system; advance formal care coordination; increase public awareness regarding the inadequacies of developmentally disabled care in order to advance systemic change; promote national efforts in digital health that encourage designers and developers to consider the perspectives/experiences of the IDD community within the design process; social policy research; and identify barriers to high-quality healthcare access.

The purpose of this funding opportunity announcement (FOA) is to support innovative, multidisciplinary, interactive, and synergistic program projects that integrate basic, translational, and clinical approaches to understanding the developmental biology and genetic basis of significant congenital human malformations. To contain costs, each program project will consist of only three component research projects, as well as associated cores. At least one project must use basic research in an animal model system and at least one project must be clinical or translational in nature. The component research projects must share a common central theme, focus, or objective on a specific major developmental defect or malformation that is genotypically, mechanistically, biologically, or phenotypically analogous or homologous in both animal models and humans. Any non-mammalian or mammalian animal model may be used, as long as it contributes to the common overall theme or objective of the program project.  The component research projects should share a common developmental gene, process, mechanism, pathway, or phenotype.

The purpose of this Funding Opportunity Announcement (FOA) is to seek applications for the Developmental Centers for Interdisciplinary Research in Benign Urology Program (P20). Among the goals of this Program is to further advance research in benign genitourinary diseases and disorders by building research teams and facilitating resources generation and sharing. The research teams should be composed of individuals with complementary expertise who propose to either develop innovative resources (Resource Development Projects) or a new research project (Scientific Research Projects) that utilize integrative approaches to address questions relevant to benign genitourinary diseases or disorders. While NIH defined clinical trials are not allowed, studies involving human subjects or tissues are encouraged. Resources developed by the Resource Development Projects will be shared upon validation while resources developed within the Scientific Research Projects will be shared at the end or termination of the award, as appropriate and consistent with the program goal of further advancing research. Each Developmental Center is centered on a single Project and must contain an Administrative Core and an Educational Enrichment Program. As part of the efforts of the Division of Kidney, Urologic and Hematologic Diseases (DKUH) to expand and enhance benign urology research, the Developmental Centers Program will work in partnership with the George M. O'Brien Urology Cooperative Research Centers Program (U54) and the Multidisciplinary K12 Urologic Research (KURe and UroEpi) Career Development Programs.

The purpose of this FOA is to enhance the capacity of surveillance programs to implement or enhance a population-based, multiple-source surveillance program for autism spectrum disorder (ASD) and other developmental disabilities (DDs) that co-occur with ASD (cerebral palsy (CP) and intellectual disability (ID)). The project will fund sites to participate in the Autism and Developmental Disabilities Monitoring (ADDM) Network and will enhance surveillance activities at both prior and newly participating sites through two funding components. Component A funds surveillance of autism spectrum disorder (ASD) and other DDs (i.e. CP and ID) among 8-year-olds. Component B funds surveillance of ASD among 4-year-olds. Component A is required for all applicants, while applying for Component B funding is optional. In this FOA, five project period short-term outcomes will be achieved through five strategies and their corresponding activities. The five expected outcomes include: improved understanding of ASD & other DDs, including trends and disparities in ASD prevalence over time; improved understanding of the implications of the change from DSM-IV TR to DSM-5 diagnostic criteria for ASD; stronger relationships with partners and data sources; increased dissemination of ADDM data; improved reliability and efficiency of ADDM surveillance.

People With Disabilities Foundation (PWDF), an IRS § 501(c)(3) public, nonprofit agency that serves people with psychiatric and/or developmental disabilities, is pleased to announce Phase 2 of its pilot grant program. PWDF's mission is to provide education and advocacy for people with psychiatric and/or developmental disabilities, so that they can achieve equal opportunities in all aspects of life.  PWDF currently accomplishes its mission through two programs:   Advocacy and Public Awareness and Education. PWDF is continuing the development of its grant program.  Grants may be used for a specific program, project, or general operating expenses if related to a specific project or program in furtherance of providing advocacy, education, vocational, or other services to people with psychiatric and/or developmental disabilities. It is anticipated that this pilot program will award smaller grants in the range of $5,000 to $12,500, with a goal of future program expansion that will make larger awards. Letters of Interest are due November 6, 2017.

This funding opportunity announcement (FOA) encourages applications from institutions/organizations that propose to develop informative outcome measures for use in clinical trials for individuals with intellectual and developmental disabilities (IDD). This FOA will address a significant need in the field, one that is especially apparent in efforts to develop pharmacological treatments for these populations. This FOA will focus ongoing clinical and translational research on a neglected area essential for therapy and pharmacological treatment development. Potential applicants may also be interested in the FOA "Preclinical Research on Model Organisms to Predict Treatment Outcomes for Disorders Associated with Intellectual and Developmental Disabilities (R01)."

The NICHD Exploratory/Developmental Grant program supports exploratory and developmental research projects that fall within the NICHD mission by providing support for the early and conceptual stages of these projects. These studies may involve considerable risk but may lead to a breakthrough in a particular area, or to the development of novel techniques, agents, methodologies, models, or applications that could have a major impact on a field of biomedical, behavioral, or clinical research.

The NIH Exploratory/Developmental Grant supports exploratory and developmental research projects by providing support for the early and conceptual stages of these projects. These studies may involve considerable risk but may lead to a breakthrough in a particular area, or to the development of novel techniques, agents, methodologies, models, or applications that could have a major impact on a field of biomedical, behavioral, or clinical research. This Parent Funding Opportunity Announcement is for basic science experimental studies involving humans, referred to in NOT-OD-18-212 as prospective basic science studies involving human participants. These studies fall within the NIH definition of a clinical trial and also meet the definition of basic research. Types of studies that should submit under this FOA include studies that prospectively assign human participants to conditions (i.e., experimentally manipulate independent variables) and that assess biomedical or behavioral outcomes in humans for the purpose of understanding the fundamental aspects of phenomena without specific application towards processes or products in mind. Studies conducted with specific applications toward processes or products in mind should submit under the appropriate Clinical Trials Required or Clinical Trial Optional FOA. The proposed project must be related to the programmatic interests of one or more of the participating NIH Institutes and Centers (ICs) based on their scientific missions.

The NIH Exploratory/Developmental Grant supports exploratory and developmental research projects by providing support for the early and conceptual stages of these projects. These studies may involve considerable risk but may lead to a breakthrough in a particular area, or to the development of novel techniques, agents, methodologies, models, or applications that could have a major impact on a field of biomedical, behavioral, or clinical research. This Parent Funding Opportunity Announcement requires that at least 1 clinical trial be proposed. The proposed project must be related to the programmatic interests of one or more of the participating NIH Institutes and Centers (ICs) based on their scientific missions. Applicants should note that some ICs (see Related Notices) only accept applications proposing mechanistic studies that meet NIH's definition of a clinical trial through this funding opportunity announcement.

The NIH Exploratory/Developmental Grant supports exploratory and developmental research projects by providing support for the early and conceptual stages of these projects. These studies may involve considerable risk but may lead to a breakthrough in a particular area, or to the development of novel techniques, agents, methodologies, models, or applications that could have a major impact on a field of biomedical, behavioral, or clinical research.

This notice announces the opportunity to apply for funding under the Innovations in Care Coordination for Children and Youth with Autism Spectrum Disorders (ASD) and Other Developmental Disabilities (DD) Program. The purpose of this program is to build on past HRSA programs (HRSA-16-048 and HRSA-13-207) to improve access to coordinated and integrated care for children with, or at risk for, ASD/DD and their families in medically underserved areas and populations.[1],[2] The purpose and objectives of this program will be accomplished by implementing the following two strategies: Family Navigation - Increasing family navigation services to improve communication between families and primary and specialty providers; link children with/at risk for ASD/DD to diagnostic evaluations, ASD/DD services, and community resources; and provide education to families of children with/at risk for ASD/DD to improve self-efficacy in navigating the system of care for children with/at risk for ASD/DD; and Provider Education - Providing education, training, and technical assistance to providers, and community based-organizations providing services to ASD/DD on improving care for children with/at risk for ASD/DD through a learning community. [1] At risk for ASD/DD can be defined as children who have been identified through primary care developmental surveillance as needing further screening or evaluation for ASD/DD. [2] HRSA definition for Medically Underserved Areas: https://datawarehouse.hrsa.gov/topics/shortageareas.aspx.

This Funding Opportunity Announcement encourages developmentally tailored research focused on adolescents and emerging adults as it relates to HIV prevention and treatment. Research is encouraged to incorporate recent advances in adolescent and young adult developmental research to optimize outcomes in HIV prevention and care research for this heterogeneous population. PA-18-651 uses the R01 grant mechanism, PA-18-652 uses the R21 mechanism, while PA-18-653 uses the R34 mechanism. High risk/high payoff projects that lack preliminary data or utilize existing data may be most appropriate for the R21 mechanism. Applicants with preliminary data and/or planning to include longitudinal analysis may wish to apply using the R01 mechanism. Applicants wanting to develop and pilot test an intervention may wish to apply using the R34 mechanism. Also listed under R21

This Funding Opportunity Announcement encourages developmentally tailored research focused on adolescents and emerging adults as it relates to HIV prevention and treatment. Research is encouraged to incorporate recent advances in adolescent and young adult developmental research to optimize outcomes in HIV prevention and care research for this heterogeneous population. PA-FY-NNN uses the R01 grant mechanism, PA-FY-NNN uses the R21 mechanism, while PA-FY-NNN uses the R34 mechanism. High risk/high payoff projects that lack preliminary data or utilize existing data may be most appropriate for the R21 mechanism. Applicants with preliminary data and/or planning to include longitudinal analysis may wish to apply using the R01 mechanism. Applicants wanting to develop and pilot test an intervention may wish to apply using the R34 mechanism.

The Centers for Disease Control and Prevention (CDC), Early Hearing Detection and Intervention (EHDI) program supports the success of all children who are deaf or hard of hearing (D/HH) in the United States by helping to ensure they receive a newborn screening, early diagnosis, and timely intervention services. Without timely screening, diagnosis and intervention, children who are D/HH lose valuable time in gaining the skills that will put them on a trajectory to have language on par with their hearing peers in kindergarten and be ready to succeed in school. Additionally, among children who are D/HH, delays in language development are more difficult to remediate with late diagnosis and intervention. While collaborative efforts by CDC, states, and other partners have helped lead to the early identification of thousands of children who are D/HH each year, their developmental and language outcomes are often unknown, and these data are not routinely collected by CDC or state EHDI programs. Furthermore, it is currently unclear what actions beyond early identification should be taken by public health to help reduce adverse consequences of hearing loss and ensure that children who are D/HH are ready for success in early childhood. The current lack of public health capacity to document and assess the intervention services and associated outcomes of early-identified children who are D/HH at the state and national level makes it challenging to: Assess the developmental progress to ensure all children who are D/HH are achieving age-appropriate milestones and are ready for success in early childhood; Identify strategies, in addition to those beyond early identification, to help assess and reduce adverse consequences of hearing loss; Assess and document the success and impact of EHDI activities across the United States.

The NIH Exploratory/Developmental Grant supports exploratory and developmental research projects by providing support for the early and conceptual stages of these projects. These studies may involve considerable risk but may lead to a breakthrough in a particular area, or to the development of novel techniques, agents, methodologies, models, or applications that could have a major impact on a field of biomedical, behavioral, or clinical research.

1) Philip R. Dodge Young Investigator Award: An award for basic science or clinical research by promising young investigators who are members of the Child Neurology Society. Applications will be judged on the basis of originality, scientific merit, succinctness, and relevance. The recipient of the Dodge award will receive a grant-in-aid of $20,000 and will be invited to present their work at the 46th Annual Meeting of the Child Neurology Society in Kansas City, MO on October 6, 2017. 2) Child Neurology Shields Research Grant: The grant supports translational or clinical research by a child neurologist or developmental pediatrician early in his/her academic career. The selected investigator will receive a $100,000 grant of $50,000 per year for two years. 3) Pediatric Epilepsy Research Foundation (PERF) Scientific Research Grant: The grant supports clinical or basic science research by a child neurologist or developmental pediatrician early in his/her academic career. The selected investigator will receive a $100,000 grant of $50,000 per year for two years.

The National Institutes of Health (NIH) Exploratory/Developmental Grant (R21) funding opportunity supports the development of new research activities in categorical program areas. The R21 activity code is intended to encourage exploratory and developmental research projects by providing support for the early and conceptual stages of these projects. These studies may involve considerable risk but may lead to a breakthrough in a particular area, or to the development of novel techniques, agents, methodologies, models, or applications that could have a major impact on a field of biomedical, behavioral, or clinical research.

The R40 MCH Autism Intervention Research Program supports applied empirical research studies to advance the evidence base on the effectiveness of interventions to improve the health and well-being of children and adolescents with autism spectrum disorders (ASD) and other developmental disabilities (DD) and to advance best practices for the screening and diagnosis of autism spectrum disorder and other developmental disabilities at an earlier age. 

This Funding Opportunity Announcement (FOA) seeks to stimulate and expand research on the interplay of genetic and environmental factors in the genesis, course, and outcomes of substance and alcohol use disorders (SUDs). Previous work in genetic epidemiology and molecular genetics has established that SUDs are highly heritable, developmental disorders with important genetic substrates.  Building on these findings, new studies using genetically informative approaches are needed to elucidate the complex interplay of genetic and environmental factors in developmental trajectories of SUDs and comorbid conditions, deepen and refine phenotypic definitions of SUDs, and meet the methodologic challenges of the field.  Such studies hold great potential to promote understanding of the true contributions of both genetic and environmental factors to initiation, progression, comorbidity, adverse outcomes, and cessation of SUDs; to elucidate mechanisms of risk; and to enhance opportunities for translation to treatment, prevention, gene-finding and molecular studies.